ATE423204T1 - Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln - Google Patents

Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln

Info

Publication number
ATE423204T1
ATE423204T1 AT97916252T AT97916252T ATE423204T1 AT E423204 T1 ATE423204 T1 AT E423204T1 AT 97916252 T AT97916252 T AT 97916252T AT 97916252 T AT97916252 T AT 97916252T AT E423204 T1 ATE423204 T1 AT E423204T1
Authority
AT
Austria
Prior art keywords
production
particles
virus
hepatitis
purification
Prior art date
Application number
AT97916252T
Other languages
English (en)
Inventor
T Liang
Thomas Baumert
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE423204T1 publication Critical patent/ATE423204T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24223—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT97916252T 1996-11-08 1997-03-25 Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln ATE423204T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3023896P 1996-11-08 1996-11-08

Publications (1)

Publication Number Publication Date
ATE423204T1 true ATE423204T1 (de) 2009-03-15

Family

ID=21853241

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97916252T ATE423204T1 (de) 1996-11-08 1997-03-25 Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln

Country Status (8)

Country Link
US (1) US6387662B1 (de)
EP (1) EP0941337B1 (de)
JP (2) JP4021493B2 (de)
AT (1) ATE423204T1 (de)
AU (1) AU738585B2 (de)
CA (1) CA2269097C (de)
DE (1) DE69739268D1 (de)
WO (1) WO1998021338A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU765940B2 (en) * 1998-06-24 2003-10-02 Innogenetics N.V. Particles of HCV envelope proteins: use for vaccination
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
CA2330837C (en) 1998-06-24 2008-11-18 Chugai Seiyaku Kabushiki Kaisha A vector expressing an rna viral full-length gene and its use
US6849429B1 (en) * 1999-11-19 2005-02-01 Board Of Regents, The University Of Texas System Viral pseudo-capsids including assembly agonists and antagonists
JP2002030098A (ja) * 2000-07-17 2002-01-29 Institute Of Immunology Co Ltd バキュロウィルスの発芽ウイルスからウイルスエンベロープを回収する方法
FR2814755B1 (fr) * 2000-09-29 2002-11-29 Agronomique Inst Nat Rech Production de particules pseudovirales de vhc en cellules d'insectes
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
WO2002097091A1 (en) * 2001-05-29 2002-12-05 University Of Miami Generation of hcv-like particles and chimeric hcv virus
US7820435B2 (en) * 2002-02-06 2010-10-26 Expression Technologies Inc. De novo synthesized plasmid, methods of making and use thereof
GB0215617D0 (en) * 2002-07-08 2002-08-14 Univ Leeds Use of hepatitis C virus (HCV) p7 protein
EP1537206B1 (de) 2002-09-13 2009-05-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infektiöse hepacivirus-pseudopartikel mit funktionellen e1-, e2-hüllproteinen
EP1742963A2 (de) * 2004-05-04 2007-01-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Herstellung und aufreinigung von west-nil-virus-ähnlichen partikeln
EP1773303A2 (de) * 2004-05-25 2007-04-18 Chimeracore, Inc. Selbstmontierendes nanopartikel-wirkstofffreisetzungssystem
DE602005026545D1 (de) 2004-08-24 2011-04-07 Tokyo Metropolitan Org Med Res Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz
CU23496A1 (es) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
JP5086082B2 (ja) * 2004-10-01 2012-11-28 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Ｃ型肝炎ウイルス複製系
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
CA2648581A1 (en) * 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating b- cell malignancies
WO2007128048A1 (en) * 2006-05-02 2007-11-15 The Macfarlane Burnet Institute For Medical Research And Public Health Limited A hepatitis c vaccine delivery vehicle
WO2007144886A2 (en) 2006-06-15 2007-12-21 Ben-Gurion University Of The Negev Research And Development Authority Virus-like particles for treatment of viral infections
JP5642972B2 (ja) 2007-02-21 2014-12-17 ユニバーシティー オブ マサチューセッツＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
WO2008113011A2 (en) 2007-03-14 2008-09-18 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
CA2683063A1 (en) * 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
JPWO2011040535A1 (ja) 2009-09-30 2013-02-28 東レ株式会社 Ｃ型肝炎ウイルスワクチン組成物
CA2847888A1 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
KR102089477B1 (ko) 2012-08-31 2020-03-17 더 가버너스 오브 더 유니버시티 오브 알버타 1차 인간 간세포의 표현형을 갖는 세포를 생성하기 위한 방법 및 조성물
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
US10188710B2 (en) * 2013-11-04 2019-01-29 Rhode Island Council On Postsecondary Education Regulatory T cell epitope and hepatitis C virus homolog
EP3445396A4 (de) 2016-04-22 2020-03-11 Integrated Research Associates, LLC Verbessertes verfahren zur herstellung von virusähnlichen partikeln
WO2026062394A1 (en) * 2024-09-20 2026-03-26 Oxford University Innovation Limited Viral molecules

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (de) 1967-05-23 1971-08-02 Pharmacia Ab
DE3445816C1 (de) 1984-12-15 1986-06-12 Behringwerke Ag, 3550 Marburg Flaechenfoermiges diagnostisches Mittel
US4956302A (en) 1987-09-11 1990-09-11 Abbott Laboratories Lateral flow chromatographic binding assay device
US5712088A (en) 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5714596A (en) 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
CA1312544C (en) 1987-12-21 1993-01-12 James L. Wilcox Chromatographic binding assay devices and methods
ATE161041T1 (de) 1989-08-25 1997-12-15 Chiron Corp Verfahren zur hcv-züchtung in zell-linien aus b- oder t-lymphozyten
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
US5096837A (en) 1990-02-08 1992-03-17 Pacific Biotech, Inc. Immunochromatographic assay and method of using same
SK286106B6 (sk) 1990-11-08 2008-03-05 Novartis Vaccines & Diagnostics, Inc. Spôsob vykonávania imunodiagnostickej skúšky na detekciu protilátky proti vírusu hepatitídy C
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
RU2212899C2 (ru) 1991-09-13 2003-09-27 Чирон Корпорейшн Hcv иммунореактивные полипептидные композиции
KR0172970B1 (ko) * 1992-06-17 1999-02-01 김영길 Aids백신에 유용한 키메릭 단백 및 그의 제조방법
AU3241095A (en) 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
US5521102A (en) 1994-08-08 1996-05-28 Quidel Corporation Controlled sensitivity immunochromatographic assay

Also Published As

Publication number Publication date
DE69739268D1 (de) 2009-04-02
AU2347997A (en) 1998-06-03
CA2269097A1 (en) 1998-05-22
CA2269097C (en) 2007-01-09
JP2001504337A (ja) 2001-04-03
US6387662B1 (en) 2002-05-14
WO1998021338A1 (en) 1998-05-22
EP0941337B1 (de) 2009-02-18
JP4231083B2 (ja) 2009-02-25
JP2007300934A (ja) 2007-11-22
EP0941337A1 (de) 1999-09-15
JP4021493B2 (ja) 2007-12-12
AU738585B2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
ATE423204T1 (de) Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln
DE69332334D1 (de) Verfahren zur verstärkten expression von virusproteinen
DE69535018D1 (de) Papillomavirus vakzine
EP0484787A3 (en) Hcv-specific peptides, process for obtaining them and their use
NL300324I1 (nl) Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze
ATE333501T1 (de) Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus- ähnlichen tielchen (vlps)
NO304380B1 (no) FremgangsmÕte for fremstilling av et hepatitt C-virus (HCV) asialoglykoprotein
AU8223187A (en) T cell epitopes of the hepatitis b virus nucleocapsid protein
DK0732340T3 (da) Ekspression af porcine reproduktions- og respirationssyndromviruspolypeptider i den samme celle
MX9708678A (es) Proteasa activa, soluble del virus de la hepatitis c.
DE69841015D1 (de) Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
EP0970115A4 (de) Virale peptide mit struktureller homologie zu protein g aus respiratory syncytial virus (rsv)
EP0967223A3 (de) Hepatitis C Virus Peptidantigene und Verfahren zur Bestimung von Hepatitis C Virus (HCV)
RU93043621A (ru) Способы получения гликопротеинов нсv, способ очистки, аналитический набор, способ выявления нсv, способ элиминации нсv, способ индукции иммунитета, гликопротеины, иммунореагенты
ITRM20010336A1 (it) Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi
EP0888046A4 (de) Verfahren zur proteinproduktion mittels eines mitochondrialen translationssystems.
WO1997027742B1 (en) Method of protein production using mitochondrial translation system
ATE111488T1 (de) Rekombiniebares hepatitis-delta-antigen, verfahren zu seiner reinigung und verwendung.
DE69738969D1 (de) Verfahren zur expression und herstellung des rekombinanten proteins gp90 der glykoproteinhülle des infektiösen pferdeanämievirus eiav
FI971702L (fi) Hepatiitti-C-viruksen asialoglykoproteiinit
NO950527D0 (no) Analogifremgangsmåte ved fremstilling av non-A, non-B hepatittvirus-antigenpeptid

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties